It is well-known that consistently high hepatitis B virus (HBV) DNA levels increase the risk of fibrosis progression and hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB) \[[@b1-cmh-2020-0099],[@b2-cmh-2020-0099]\]. Therefore, the primary goal of CHB treatment is complete suppression of HBV DNA by antiviral treatment \[[@b3-cmh-2020-0099]\]. Before the introduction of nucleos(t)ide analogues (NAs) with a high genetic barrier, such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF), long-term treatment of NAs with a low genetic barrier, such as lamivudine (LAM), adefovir dipivoxil (ADV) and telbivudine (LdT), led to drug resistance in many CHB patients \[[@b3-cmh-2020-0099]-[@b5-cmh-2020-0099]\]. Until the introduction of ETV or TDF, the standard treatment was to add ADV to LAM or LdT for the treatment of CHB patients with LAM or LdT resistance \[[@b6-cmh-2020-0099]\]. However, CHB patients receiving LAM or LdT/ADV combination therapy often show a suboptimal response \[[@b7-cmh-2020-0099]\]. In patients with this suboptimal response, it is known that the risk of developing resistance to various NAs increases, as well as the risk of developing end-stage liver disease and HCC \[[@b8-cmh-2020-0099]\]. Therefore, the current guidelines recommended that HBV DNA maintain serum HBV DNA level below the detection limit of real-time polymerase chain reaction as the primary treatment goal \[[@b3-cmh-2020-0099],[@b5-cmh-2020-0099],[@b9-cmh-2020-0099]\]. In the past, a combination of ETV-based regimens had been attempted to treat the CHB patients who had suboptimal response to LAM or LdT/ADV combination therapy \[[@b10-cmh-2020-0099],[@b11-cmh-2020-0099]\]. However, since the introduction of TDF with strong antiviral efficacy in the treatment of CHB, TDF monotherapy or TDF+other NAs regimens have been attempted to treat patients with various drug resistance \[[@b12-cmh-2020-0099]-[@b16-cmh-2020-0099]\]. Berg et al. \[[@b12-cmh-2020-0099]\] conducted a prospective randomized controlled trial to compare the antiviral effects of TDF monotherapy and TDF+emtricitabine (FTC) combination therapy in patients with suboptimal responses to ADV. According to the results of their study, complete virologic response (CVR) of TDF monotherapy and TDF+FTC combination therapy groups was 81% and 81%, respectively, at 48 weeks; and there was no difference between the two groups \[[@b12-cmh-2020-0099]\]. In a retrospective study of CHB patients with suboptimal response to ADV with or without NAs in LAM-resistant CHB, Cho et al. \[[@b13-cmh-2020-0099]\] showed that the CVR of TDF monotherapy group and TDF with NA combination group at 48 weeks was 81.8% and 85.9%, respectively; and there was also no significant difference between the two groups (*P* =0.075). In a small randomized controlled trial, Lee et al. \[[@b14-cmh-2020-0099]\] compared the antiviral efficacy between switching to TDF+NAs therapy and continuing current ADV+NA therapy in patients with suboptimal response to ADV-based therapy. The results of their study showed that TDF+NAs therapy was significantly higher in CVR compared to continued ADV+NA (87.5% vs. 37.5% at 48 weeks, P =0.002) \[[@b14-cmh-2020-0099]\]. In addition, TDF showed good effects on CHB patients with ETV, ADV resistance, and multidrug resistance, as well as LAM resistance \[[@b15-cmh-2020-0099],[@b16-cmh-2020-0099]\]. Lim et al. \[[@b15-cmh-2020-0099]\] compared the effects of TDF monotherapy versus TDF and ETV combination therapy in patients with ETV-resistant CHB with multiple drug failure in a randomized controlled trial, and the CVR of TDF and TDF+ETV groups was 71% and 73%, respectively, at 48 weeks. There was no difference between the two groups (*P* =0.99) \[[@b15-cmh-2020-0099]\]. In a study comparing the effects of TDF monotherapy versus TDF and ETV combination therapy in ADV-resistant CHB patients with multiple drug failure, the CVR at 48 weeks was 62% and 63.5% for TDF and TDF/ETV groups, respectively; and there was also no significant difference between the two groups (*P* =0.88) \[[@b16-cmh-2020-0099]\]. Moreover, the results of several different studies showed no difference in CVR between TDF monotherapy and TDF+ETV combination therapy, the combination regimen of the most potent NAs to date, in CHB patients who are resistant to various NAs ([Table 1](#t1-cmh-2020-0099){ref-type="table"}).

Woo et al. conducted a prospective randomized controlled study to compare the effectiveness and efficacy between TDF+ETV therapy and LAM/LdT+ADV maintenance therapy for LAM-resistant patients who had suboptimal responses to LAM+ADV combination therapy. As predicted from the results of many previous clinical studies, the results of this study showed that TDF+ETV group had a significantly higher CVR at 48 weeks compared to LAM/LdT+ADV maintenance therapy group (93.33% vs. 6.52%, *P*\<0.001). The clinical significance of this study was to confirm the expected results based on the results of previous retrospective studies through prospective trials. However, based on the results of several studies, including the studies conducted by Lim et al., \[[@b15-cmh-2020-0099],[@b16-cmh-2020-0099]\] TDF monotherapy alone was expected to have a sufficient effect even in patients with suboptimal responses to LAM+ADV. Therefore, this study had a significant limitation of not comparing the effect of TDF monotherapy group to that of TDF+ETV group. In real clinical practice, most patients with LAM+ADV suboptimal responses have already been treated with either TDF monotherapy or TDF+NAs combination therapy. Therefore, the results of this study may be considered a little late to have practical significance in clinical practice. Recently, patients who participated in the two aforementioned studies conducted by Lim et al. \[[@b17-cmh-2020-0099]\] reported the results of treatment for 244 weeks after switching from TDF+ETV to TDF monotherapy at 48 weeks. The CVR in ETV and ADV resistance groups increased to 84.4% and 73.5%, respectively, at 240 weeks; and there was no significant difference between the two groups (*P* =0.07). However, eGFR and bone mineral density were significantly decreased at the 240-week time point compared to the baseline (*P*\<0.001), reflecting the concern about the safety of long-term use of TDF \[[@b17-cmh-2020-0099]\]. Due to these adverse effects of TDF, tenofovir alafenamide (TAF) has been recommended recently, especially in patients who are at risk of developing renal or bone disease \[[@b3-cmh-2020-0099],[@b5-cmh-2020-0099]\]. Therefore, in the future, clinical studies are needed to verify the effectiveness of TAF-based regimens in patients with CHB who are resistant or suboptimal to various NAs.
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:   adefovir dipivoxil
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Summary of anti-viral efficacy results of tenofovir-based therapy in patients with suboptimal response or resistance to NAs

  Study                                         Study design    Study population                                                  Intervention                                Primary efficacy end point                  Virologic response
  --------------------------------------------- --------------- ----------------------------------------------------------------- ------------------------------------------- ------------------------------------------- -----------------------------
  Berg et al. \[[@b12-cmh-2020-0099]\] (2010)   Prospective     Suboptimal response to ADV                                        TDF (n=53) vs. TDF/FTC (n=52)               HBV DNA level \<400 copies/mL at 48 weeks   81% vs. 81% (*P*=NS)
  Cho et al. \[[@b13-cmh-2020-0099]\] (2015)    Retrospective   Suboptimal response to ADV with or without NAs in LAM-resistant   TDF (n=18) vs. TDF/NA (n=107)               HBV DNA level \<20 IU/mL at 48 weeks        81.8% vs. 85.9% (*P*=0.750)
  Lee et al. \[[@b14-cmh-2020-0099]\] (2016)    Prospective     Partial responses to ADV+NA therapy for NA resistance             TDF/NA (n=16) vs. continued ADV/NA (n=16)   HBV DNA level \<60 IU/mL at 48 weeks        81.3% vs. 56.3% (P\<0.001)
  Lim et al. \[[@b15-cmh-2020-0099]\] (2016)    Prospective     ETV-resistant                                                     TDF (n=45) vs. TDF/ETV (n=45)               HBV DNA level \<15 IU/mL at 48 weeks        71% vs. 73% (*P*=0.99)
  Lim et al. \[[@b16-cmh-2020-0099]\] (2016)    Prospective     ADV-resistant                                                     TDF (n=50) vs. TDF/ETV (n=52)               HBV DNA level \<15 IU/mL at 48 weeks        62% vs. 63.5% (*P*=0.88)

NA, nucleos(t)ide analogue; ADV, adefovir dipivoxil; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; HBV, hepatitis B virus; NS, not significant; LAM, lamivudine; ETV, entecavir.
